Drugs / TS1-ASO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07600658 | Sep 2026 → Dec 2029 expected | CACNA1C-related disorder | Stanford University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TS1-ASO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07600658 ↗ |
| Modality | Antisense oligonucleotide | “an antisense oligonucleotide (TS1-ASO)” NCT07600658 ↗ |
| Route | Intrathecal | “Receive intrathecal injections of TS1-ASO via lumbar puncture” NCT07600658 ↗ |
| Target | CACNA1C | “designed to modulate pre-Messenger RNA (mRNA) splicing of CACNA1C by reducing inclusion of exon 8A and promoting expression of exon 8” NCT07600658 ↗ |